PegBio Co., Ltd. (PGBCY)

Market Cap	184.53M -92.8%
Revenue (ttm)	n/a
Net Income	-48.71M
EPS	-2.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	7.45
Previous Close	7.45
Day's Range	7.45 - 7.45
52-Week Range	7.45 - 7.45
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 25, 2026

About PegBio

PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company’s PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 53
• Stock Exchange: OTCMKTS
• Ticker Symbol: PGBCY

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Alpha Vantage

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Alpha Vantage.

Last checked:

Nov 9, 2026

Data Sources Report a data error